Wetherby, United Kingdom

Avacta is a UK-based biopharmaceutical company developing novel cancer immunotherapeutics and high performing diagnostics, based on its two proprietary platforms: Affimer and pre|CISION.


Investment Perspective

Avacta employs its two proprietary platforms, Affimer and pre|CISION, to create novel diagnostic and therapeutic products. The COVID-19 pandemic thrust its ability to develop an Affimer-based LFT (lateral flow test) diagnostic into the spotlight, even though we believe greater long-term value lies within Therapeutics applications. While the COVID-19 opportunity didn’t pan out as many investors expected, it did showcase Avacta’s diagnostics capabilities and Affimers’ potential. Lead therapeutic asset AVA6000 is progressing through Phase I and should confirm the clinical utility of pre|CISION. A wider portfolio of products is being readied to exploit the platform’s tumour specific activation, which should result in greater potency and less toxicity. News flow over the next 18-24 months provides multiple value-inflection points. Our valuation is £557m, equivalent to 219p/share, from £710m, 280p/share previously.

Market information

SymbolPrimary exchanges


Diagnostics M&A-led growth strategy is ready to Launch
Lighthouse | 18 Oct 2022
Building Tx and Dx portfolios from proprietary platforms
Lighthouse | 29 Sep 2022
AVA6000 set for third dose escalation stage
Lighthouse | 30 Jun 2022

Recent News

Result of the Open Offer
08 Nov 2022
Avacta to present at Theranostics FAP summit
31 Oct 2022
Result of placing
18 Oct 2022
Proposed placing, open offer and issue of convertible bonds
18 Oct 2022